NGL Fine-Chem profit and loss

Latest FY26

Revenue: ₹501cr+36.0% on FY25
EBITDA: ₹72.7cr+114.6% on FY25
Net profit: ₹48.1cr+127.8% on FY25
EPS: ₹77.90+127.8% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023

Expenses
	536	501	368	339	278
	16.6	14.7	8.6	14.1	5.5
	553	516	377	353	284
	272	247	182	171	116
	−23.3	−7.7	−0.0	−12.1	23.9
	68.7	65.5	55.5	45.1	36.9
	4.2	4.5	2.3	1.3	1.2
	20.6	19.6	12.5	11.6	11.3
	134	123	96.4	81.6	66.6
	477	452	349	298	256
	84.2	72.7	33.9	53.3	34.3
	63.6	53.1	21.4	41.6	23.0
Profit
	75.9	63.4	27.7	54.4	27.4
	75.9	63.4	27.7	54.4	27.4
	19.2	16.1	6.2	12.2	7.4
	−0.5	−0.8	0.4	0.9	−0.5
	18.7	15.2	6.6	13.1	6.9
	57.2	48.1	21.1	41.3	20.5
	57.2	48.1	21.1	41.3	20.5
	−0.4	−0.2	−0.2	−0.2	−0.1
	56.8	47.9	20.9	41.2	20.4
	—	—	—	41.3	20.5
Per share
	₹92.59	₹77.90	₹34.19	₹66.88	₹33.18
	₹92.59	₹77.90	₹34.19	₹66.88	₹33.18
Other comprehensive income — detail
	−0.4	−0.2	−0.2	—	—
	—	−0.3	—	—	—
	−0.4	−0.1	0.3	—	—
	—	—	—	0.2	0.1
	—	0.0	−0.1	—	—
	—	—	—	−0.1	−0.0
	—	—	—	41.3	20.5
Per share — as-filed variants
	₹92.59	₹77.90	₹34.19	₹66.88	₹33.18
	₹92.59	₹77.90	₹34.19	₹66.88	₹33.18
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	287	261	186	180	138
	53.5%	52.2%	50.5%	53.1%	49.5%
Adjusted (ex-exceptional items) — derived
	75.9	63.4	27.7	54.4	27.4
	57.2	48.1	21.1	41.3	20.5
	₹92.59	₹77.90	₹34.19	₹66.88	₹33.18

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

NGLFINE₹2,610.60

NGL Fine-Chem Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersSYNCOMF JAGSNPHARM HESTERBIOAMRUTANJAN WINDLAS INDOCO SAIPARENTMcap ₹1,613 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	278.1	338.7	368.3	501.0	536.2
Other Income	5.5	14.1	8.6	14.7	16.6
Total Income	283.6	352.8	376.9	515.7	552.7
Expenses
+ Cost of Materials Consumed	116.4	170.8	182.4	247.2	272.4
+ Changes in Inventories	23.9	-12.1	-0.0	-7.7	-23.3
+ Employee Benefit Expense	36.9	45.1	55.5	65.5	68.7
+ Finance Costs	1.2	1.3	2.3	4.5	4.2
+ Depreciation & Amortisation	11.3	11.6	12.5	19.6	20.6
+ Other Expenses	66.6	81.6	96.4	123.3	134.2
Total Expenses	256.2	298.4	349.2	452.3	476.8
EBITDA	34.3	53.3	33.9	72.7	84.2
EBIT	23.0	41.6	21.4	53.1	63.6
Profit
PBT before Exceptional Items	27.4	54.4	27.7	63.4	75.9
Pretax Income	27.4	54.4	27.7	63.4	75.9
+ Current Tax	7.4	12.2	6.2	16.1	19.2
+ Deferred Tax	-0.5	0.9	0.4	-0.8	-0.5
Tax Expense	6.9	13.1	6.6	15.2	18.7
Net Income	20.5	41.3	21.1	48.1	57.2
+ Net Income — Continuing Ops	20.5	41.3	21.1	48.1	57.2
+ Other Comprehensive Income	-0.1	-0.2	-0.2	-0.2	-0.4
Total Comprehensive Income	20.4	41.2	20.9	47.9	56.8
Net Income to Common	20.5	41.3	—	—	—
Per Share
Basic EPS	33.18	66.88	34.19	77.90	92.59
Diluted EPS	33.18	66.88	34.19	77.90	92.59
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-0.2	-0.2	-0.4
+ Items NOT to be Reclassified to P&L	—	—	—	-0.3	—
+ Tax on Items NOT to be Reclassified	—	—	0.3	-0.1	-0.4
+ Tax on Items NOT to be Reclassified — alt tag	0.1	0.2	—	—	—
+ Tax on Items to be Reclassified	—	—	-0.1	0.0	—
+ Tax on Items to be Reclassified — alt tag	-0.0	-0.1	—	—	—
Comprehensive Income — Owners of Parent	20.5	41.3	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	33.18	66.88	34.19	77.90	92.59
Diluted EPS — Continuing Operations	33.18	66.88	34.19	77.90	92.59
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	137.8	180.0	185.9	261.5	287.1
Gross Margin %	49.54	53.15	50.47	52.19	53.54
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	27.4	54.4	27.7	63.4	75.9
Net Income Adj (tax-effected)	20.5	41.3	21.1	48.1	57.2
EPS Adj	33.18	66.88	34.19	77.90	92.59
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	5.00	5.00	5.00	5.00	5.00
Filed Debt Equity	—	—	—	0.37	—
Filed Dscr	—	—	—	0.03	—
Filed Iscr	—	—	—	13.41	—
Paid Up Equity Capital	3.1	3.1	3.1	3.1	3.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.